首页 > 最新文献

Hematological Oncology最新文献

英文 中文
Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation 一家拉丁美洲中心对低收入群体晚期套细胞淋巴瘤的治疗结果:门诊造血干细胞移植的作用
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-04-12 DOI: 10.1002/hon.3271
José Carlos Jaime-Pérez, Marcela Hernández-Coronado, Mariana González-Treviño, Renata V. Barragán-Longoria, Eugenia M. Ramos-Dávila, David Gómez-Almaguer
{"title":"Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation","authors":"José Carlos Jaime-Pérez, Marcela Hernández-Coronado, Mariana González-Treviño, Renata V. Barragán-Longoria, Eugenia M. Ramos-Dávila, David Gómez-Almaguer","doi":"10.1002/hon.3271","DOIUrl":"https://doi.org/10.1002/hon.3271","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140546857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203 分析利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松一线治疗患者两年内疾病进展和组织学转化的风险因素:对 JCOG0203 中晚期滤泡性淋巴瘤患者的 15 年随访
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-04-10 DOI: 10.1002/hon.3272
Takashi Watanabe, Yoshihiro Matsuno, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Kunihiro Tsukasaki, Kensei Tobinai, Hirokazu Nagai

Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment, we performed this post-hoc analysis of patients with advanced indolent B-cell lymphoma in a randomized clinical trial wherein six cycles of R-CHOP were administered every 2–3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676–9.466) and high- (OR 2.236, 95% CI 0.160–31.226) risks, B symptoms (OR 2.091, 95% CI 0.747–5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634–5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow-up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806–8.575) and high-risk FLIPI (OR 4.401, 95% CI 0.186–104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analysis had a greater impact on HT. G3A and high-risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced-stage FL in future trials, particularly to address the unmet needs of patients with POD24.

滤泡性淋巴瘤(FL)是一种惰性淋巴瘤,由于组织学转化(HT)而变得具有侵袭性,导致生存率降低。FL患者的临床病程和治疗方案各不相同。一些患者的生存期较短,并在诊断/治疗后 24 个月内(POD24)出现疾病进展;最佳治疗方法仍是一个未满足的需求。因此,确定预测生存期缩短的因素对于分层治疗和延长 FL 患者的生存期至关重要。为了分析利妥昔单抗加环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)一线治疗患者POD24和HT的风险因素,我们对一项随机临床试验中的晚期惰性B细胞淋巴瘤患者进行了这项事后分析,该试验每2-3周进行6个周期的R-CHOP治疗。主要分析结果显示疗效无差异,因此我们对分配到两组的248名FL患者进行了分析。300 名入选患者的所有组织病理学标本均由三位血液病理学专家进行了审查。多变量分析显示,滤泡性淋巴瘤国际预后指数(FLIPI)中级(几率比[OR] 2.531,95% 置信区间[CI] 0.676-9.466)和高级(OR 2.236,95% CI 0.160-31.226)风险、B 症状(OR 2.091,95% CI 0.747-5.851)和 3A 级(G3A)(OR 1.833,95% CI 0.634-5.299)是 POD24 的风险因素。此外,中位随访 15.9 年的多变量分析显示,G3A(OR 2.628,95% CI 0.806-8.575)和高风险 FLIPI(OR 4.401,95% CI 0.186-104.377)是 HT 的风险因素。然而,仅限于前10年的分析显示,长期分析中阐明的预后因素对高血压的影响更大。G3A和高风险FLIPI可独立预测POD24和HT,从而在未来的试验中为未经治疗的晚期FL患者的治疗分层提供信息,特别是为了满足POD24患者尚未得到满足的需求。
{"title":"Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203","authors":"Takashi Watanabe,&nbsp;Yoshihiro Matsuno,&nbsp;Masashi Wakabayashi,&nbsp;Dai Maruyama,&nbsp;Kazuhito Yamamoto,&nbsp;Nobuko Kubota,&nbsp;Kazuyuki Shimada,&nbsp;Kohsuke Asagoe,&nbsp;Motoko Yamaguchi,&nbsp;Kiyoshi Ando,&nbsp;Michinori Ogura,&nbsp;Junya Kuroda,&nbsp;Youko Suehiro,&nbsp;Kunihiro Tsukasaki,&nbsp;Kensei Tobinai,&nbsp;Hirokazu Nagai","doi":"10.1002/hon.3272","DOIUrl":"https://doi.org/10.1002/hon.3272","url":null,"abstract":"<p>Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment, we performed this post-hoc analysis of patients with advanced indolent B-cell lymphoma in a randomized clinical trial wherein six cycles of R-CHOP were administered every 2–3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676–9.466) and high- (OR 2.236, 95% CI 0.160–31.226) risks, B symptoms (OR 2.091, 95% CI 0.747–5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634–5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow-up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806–8.575) and high-risk FLIPI (OR 4.401, 95% CI 0.186–104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analysis had a greater impact on HT. G3A and high-risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced-stage FL in future trials, particularly to address the unmet needs of patients with POD24.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140541039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis 新型单克隆抗体:轻链淀粉样变性病的真正特异性疗法
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-04-09 DOI: 10.1002/hon.3270
Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti-amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.

轻链淀粉样变性是一种罕见疾病,由骨髓中的克隆浆细胞产生过量的免疫球蛋白轻链引起。这些轻链发生错误折叠并产生不溶性纤维,沉积在各种器官中,包括心脏、肾脏、肝脏、神经系统和消化道。预期寿命和病程中的症状因受影响器官和受影响器官的数量而异。靶向浆细胞疗法大大推进了淀粉样变性病的临床治疗,并不断取得进展。然而,目前的临床研究正在研究创新的靶点、药物组合和治疗策略,以通过最大限度地减少不良反应和改善这些具有挑战性的血液病患者的预后来改善治疗效果。在本文中,我们回顾了抗淀粉样蛋白抗体的使用现状,它是当前淀粉样蛋白治疗中一种革命性的创新方法。
{"title":"Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis","authors":"Maria Livia Del Giudice,&nbsp;Sara Galimberti,&nbsp;Gabriele Buda","doi":"10.1002/hon.3270","DOIUrl":"https://doi.org/10.1002/hon.3270","url":null,"abstract":"<p>Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti-amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group B细胞急性淋巴细胞白血病中与RAS信号通路突变相关的预后:华南儿童白血病研究组的报告
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-04-02 DOI: 10.1002/hon.3265
Xinyu Li, Shaofen Lin, Ning Liao, Huirong Mai, Xingjiang Long, Lili Liu, Beiyan Wu, Qiwen Chen, Qian Kong, Xianling Kong, Lixia Liu, Jiayue Qin, Jianpei Fang, Dunhua Zhou

The next-generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the RAS signaling pathway mutation spectrum and the related prognosis in pediatric ALL. We employed an NGS panel comprising 220 genes. NGS results were collected from 202 pediatric ALL patients. 155 patients (76.7%) harbored at least one mutation. The incidences of RAS signaling pathway mutations are different significantly between T-ALL and B-ALL. In B-ALL, the RAS pathway is mostly involved, and NRAS (17.6%), KRAS (22.7%), and PTPN11 (7.7%) were the three most frequently mutated genes. Co-occurring mutations of CREBBP and NRAS, FLT3, or PTPN11 (p = 0.002, p = 0.009, and p = 0.003, respectively) were found in this cohort. The 3-year RFS rates for the RAS signaling pathway mutation-positive and negative cases was 76.5 % versus 89.7 % (p = 0.012). Four cases relapsed in the lately 3 years were RAS signaling pathway mutation-positive. RAS signaling pathway mutation is an important biomarker for poorer relapse-free survival in pediatric B-ALL patients despite good early MRD levels.

新一代测序技术的应用在小儿急性淋巴细胞白血病(ALL)中经常发现新的基因改变。RAS信号通路突变在ALL复发时常表现为发病时的小亚克隆,被认为是ALL复发的驱动因素。RAS信号通路中的亚克隆改变是否应考虑用于ALL治疗的风险分层,目前还没有定论。在这项工作中,我们研究了儿童 ALL 中 RAS 信号通路突变谱及相关预后。我们采用了一个包含 220 个基因的 NGS 面板。我们收集了 202 例小儿 ALL 患者的 NGS 结果。155例患者(76.7%)至少携带一种突变。RAS 信号通路突变的发生率在 T-ALL 和 B-ALL 之间存在显著差异。在B-ALL中,RAS通路主要参与其中,NRAS(17.6%)、KRAS(22.7%)和PTPN11(7.7%)是最常发生突变的三个基因。该队列中发现了CREBBP与NRAS、FLT3或PTPN11的共存突变(分别为p = 0.002、p = 0.009和p = 0.003)。RAS信号通路突变阳性和阴性病例的3年RFS率分别为76.5%和89.7%(p = 0.012)。最近3年复发的4例患者均为RAS信号通路突变阳性。尽管早期MRD水平良好,但RAS信号通路突变是导致儿童B-ALL患者无复发生存率较低的重要生物标志物。
{"title":"The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group","authors":"Xinyu Li,&nbsp;Shaofen Lin,&nbsp;Ning Liao,&nbsp;Huirong Mai,&nbsp;Xingjiang Long,&nbsp;Lili Liu,&nbsp;Beiyan Wu,&nbsp;Qiwen Chen,&nbsp;Qian Kong,&nbsp;Xianling Kong,&nbsp;Lixia Liu,&nbsp;Jiayue Qin,&nbsp;Jianpei Fang,&nbsp;Dunhua Zhou","doi":"10.1002/hon.3265","DOIUrl":"https://doi.org/10.1002/hon.3265","url":null,"abstract":"<p>The next-generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the <i>RAS</i> signaling pathway mutation spectrum and the related prognosis in pediatric ALL. We employed an NGS panel comprising 220 genes. NGS results were collected from 202 pediatric ALL patients. 155 patients (76.7%) harbored at least one mutation. The incidences of <i>RAS</i> signaling pathway mutations are different significantly between T-ALL and B-ALL. In B-ALL, the <i>RAS</i> pathway is mostly involved, and <i>NRAS</i> (17.6%), <i>KRAS</i> (22.7%), and <i>PTPN11</i> (7.7%) were the three most frequently mutated genes. Co-occurring mutations of <i>CREBBP</i> and <i>NRAS</i>, <i>FLT3</i>, or <i>PTPN11</i> (<i>p</i> = 0.002, <i>p</i> = 0.009, and <i>p</i> = 0.003, respectively) were found in this cohort. The 3-year RFS rates for the <i>RAS</i> signaling pathway mutation-positive and negative cases was 76.5 % versus 89.7 % (<i>p</i> = 0.012). Four cases relapsed in the lately 3 years were <i>RAS</i> signaling pathway mutation-positive. <i>RAS</i> signaling pathway mutation is an important biomarker for poorer relapse-free survival in pediatric B-ALL patients despite good early MRD levels.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140343061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia KIT 突变转录本水平对监测 t(8;21)型急性髓性白血病可测量残留疾病的有用性。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-03-10 DOI: 10.1002/hon.3264
Yuan Sun, Xu Wang, Wen-Min Chen, Yue Hao, Ling-Di Li, Jin-Ying Li, Kai Sun, Zong-Yan Shi, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Ya-Zhen Qin

In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KITmut) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut (D816V/H/Y or N822K) were tested for KITmut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KITmut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KITmut-high (KIT_H) group and the KITmut-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (p = 0.0040 and 0.021, respectively) and Course 2 consolidation (p = 0.018 and 0.011, respectively) but not at diagnosis and CR. The <3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with >3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with <3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KITmut and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in t (8; 21) AML patient with KIT mutation.

据报道,除了 RUNX1::RUNX1T1 转录本水平外,使用 KIT 突变体(KITmut)DNA 水平监测可测残留疾病也可预测 t (8; 21) 急性髓性白血病(AML)的复发。然而,KITmut 转录本水平的作用仍不清楚。我们使用数字聚合酶链反应检测了 52 名 t (8; 21) 型急性髓性白血病患者在诊断时和治疗期间采集的 202 份骨髓样本的 KITmut(D816V/H/Y 或 N822K)转录本水平。通过对以下各时间点的复发情况进行接收者操作特征曲线分析,确定了 KITmut 的各个最佳临界值:诊断时、获得完全缓解 (CR) 后、疗程 1 和疗程 2 巩固后。利用截断值将患者分为 KITmut -高(KIT_H)组和 KITmut -低(KIT_L)组。KIT_H 组患者在第一疗程巩固治疗后(p = 0.0040 和 0.021,分别为 0.0040 和 0.021)和第二疗程巩固治疗后(p = 0.018 和 0.011,分别为 0.0040 和 0.021),无复发生存率(RFS)和总生存率(OS)明显低于 KIT_L 组患者,但在诊断和 CR 时则不明显。RUNX1::RUNX1T1转录物水平降低3个对数值(11/45;24.4%)的患者的RFS与Mut和RUNX1::RUNX1T1转录物水平降低3个对数值(11/45;24.4%)的患者的RFS相似。
{"title":"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia","authors":"Yuan Sun,&nbsp;Xu Wang,&nbsp;Wen-Min Chen,&nbsp;Yue Hao,&nbsp;Ling-Di Li,&nbsp;Jin-Ying Li,&nbsp;Kai Sun,&nbsp;Zong-Yan Shi,&nbsp;Hao Jiang,&nbsp;Qian Jiang,&nbsp;Xiao-Jun Huang,&nbsp;Ya-Zhen Qin","doi":"10.1002/hon.3264","DOIUrl":"10.1002/hon.3264","url":null,"abstract":"<p>In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT<sup>mut</sup>) DNA level is reportedly predictive of relapse in <i>t</i> (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT<sup>mut</sup> transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 <i>t</i> (8; 21) AML patients with KIT<sup>mut</sup> (D816V/H/Y or N822K) were tested for KIT<sup>mut</sup> transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT<sup>mut</sup> were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT<sup>mut</sup>-high (KIT_H) group and the KIT<sup>mut</sup>-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (<i>p</i> = 0.0040 and 0.021, respectively) and Course 2 consolidation (<i>p</i> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with &gt;3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KIT<sup>mut</sup> and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in <i>t</i> (8; 21) AML patient with KIT mutation.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement 18F-FDG PET/CT 和 CECT 的纹理分析:预测纵隔大块受累的霍奇金淋巴瘤的难治性。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-03-07 DOI: 10.1002/hon.3261
Elisabetta M. Abenavoli, Flavia Linguanti, Matilde Anichini, Vittorio Miele, Francesco Mungai, Marianna Palazzo, Luca Nassi, Benedetta Puccini, Ilaria Romano, Benedetta Sordi, Roberto Sciagrà, Gabriele Simontacchi, Alessandro M. Vannucchi, Valentina Berti

To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F-FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast-Enhanced Computed Tomography scan (CECT), together with clinical data, in predicting first-line therapy refractoriness (R) of classical HL (cHL) with mediastinal bulk involvement. We reviewed 69 cHL patients who underwent staging PET and CECT. Lesion segmentation and texture parameter extraction were performed using the freeware software LIFEx 6.3. The prognostic significance of clinical and imaging features was evaluated in relation to the development of refractory disease. Receiver operating characteristic curve, Cox proportional hazard regression and Kaplan-Meier analyses were performed to examine the potential independent predictors and to evaluate their prognostic value. Among clinical characteristics, only stage according to the German Hodgkin Group (GHSG) classification system significantly differed between R and not-R. Among CECT variables, only parameters derived from second order matrices (gray-level co-occurrence matrix (GLCM) and gray-level run length matrix (GLRLM) demonstrated significant prognostic power. Among PET variables, SUVmean, several variables derived from first (histograms, shape), and second order analyses (GLCM, GLRLM, NGLDM) exhibited significant predictive power. Such variables obtained accuracies greater than 70% at receiver operating characteristic analysis and their PFS curves resulted statistically significant in predicting refractoriness. At multivariate analysis, only HISTO_EntropyPET extracted from PET (HISTO_EntropyPET) and GHSG stage resulted as significant independent predictors. Their combination identified 4 patient groups with significantly different PFS curves, with worst prognosis in patients with higher HISTO_EntropyPET values, regardless of the stage. Imaging radiomics may provide a reference for prognostic evaluation of patients with mediastinal bulky cHL. The best prognostic value in the prediction of R versus not-R disease was reached by combining HISTO_EntropyPET with GHSG stage.

为识别难治性疾病高风险患者,仍需确定新的预后参数,以改善新诊断霍奇金淋巴瘤(HL)的分层。本研究探讨了从基线 18F-FDG 正电子发射/计算机断层扫描(PET)和对比增强计算机断层扫描(CECT)中提取的代谢和纹理特征与临床数据相结合,在预测纵隔大块受累的典型 HL(cHL)一线治疗难治性(R)方面的潜在价值。我们回顾了 69 例接受 PET 和 CECT 分期检查的 cHL 患者。我们使用免费软件 LIFEx 6.3 进行了病灶分割和纹理参数提取。评估了临床和影像学特征对难治性疾病发展的预后意义。通过接收者操作特征曲线、Cox比例危险回归和Kaplan-Meier分析来研究潜在的独立预测因素并评估其预后价值。在临床特征中,只有根据德国霍奇金小组(GHSG)分类系统划分的分期在R和非R之间存在显著差异。在CECT变量中,只有从二阶矩阵(灰度级共现矩阵(GLCM)和灰度级运行长度矩阵(GLRLM))得出的参数具有明显的预后能力。在 PET 变量中,SUVmean、从一阶分析(直方图、形状)和二阶分析(GLCM、GLRLM、NGLDM)得出的几个变量显示出显著的预测能力。在接收者操作特征分析中,这些变量的准确率超过 70%,其 PFS 曲线在预测难治性方面具有统计学意义。在多变量分析中,只有从 PET 中提取的 HISTO_EntropyPET (HISTO_EntropyPET)和 GHSG 分期是显著的独立预测因子。它们的组合确定了 4 个患者组,其 PFS 曲线明显不同,无论分期如何,HISTO_EntropyPET 值越高的患者预后越差。影像放射组学可为纵隔膨出型 cHL 患者的预后评估提供参考。将HISTO_EntropyPET与GHSG分期相结合,对预测R型与非R型疾病具有最佳预后价值。
{"title":"Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement","authors":"Elisabetta M. Abenavoli,&nbsp;Flavia Linguanti,&nbsp;Matilde Anichini,&nbsp;Vittorio Miele,&nbsp;Francesco Mungai,&nbsp;Marianna Palazzo,&nbsp;Luca Nassi,&nbsp;Benedetta Puccini,&nbsp;Ilaria Romano,&nbsp;Benedetta Sordi,&nbsp;Roberto Sciagrà,&nbsp;Gabriele Simontacchi,&nbsp;Alessandro M. Vannucchi,&nbsp;Valentina Berti","doi":"10.1002/hon.3261","DOIUrl":"10.1002/hon.3261","url":null,"abstract":"<p>To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F-FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast-Enhanced Computed Tomography scan (CECT), together with clinical data, in predicting first-line therapy refractoriness (R) of classical HL (cHL) with mediastinal bulk involvement. We reviewed 69 cHL patients who underwent staging PET and CECT. Lesion segmentation and texture parameter extraction were performed using the freeware software LIFEx 6.3. The prognostic significance of clinical and imaging features was evaluated in relation to the development of refractory disease. Receiver operating characteristic curve, Cox proportional hazard regression and Kaplan-Meier analyses were performed to examine the potential independent predictors and to evaluate their prognostic value. Among clinical characteristics, only stage according to the German Hodgkin Group (GHSG) classification system significantly differed between R and not-R. Among CECT variables, only parameters derived from second order matrices (gray-level co-occurrence matrix (GLCM) and gray-level run length matrix (GLRLM) demonstrated significant prognostic power. Among PET variables, SUVmean, several variables derived from first (histograms, shape), and second order analyses (GLCM, GLRLM, NGLDM) exhibited significant predictive power. Such variables obtained accuracies greater than 70% at receiver operating characteristic analysis and their PFS curves resulted statistically significant in predicting refractoriness. At multivariate analysis, only HISTO_EntropyPET extracted from PET (HISTO_Entropy<sub>PET</sub>) and GHSG stage resulted as significant independent predictors. Their combination identified 4 patient groups with significantly different PFS curves, with worst prognosis in patients with higher HISTO_Entropy<sub>PET</sub> values, regardless of the stage. Imaging radiomics may provide a reference for prognostic evaluation of patients with mediastinal bulky cHL. The best prognostic value in the prediction of R versus not-R disease was reached by combining HISTO_Entropy<sub>PET</sub> with GHSG stage.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model 原发性渗出淋巴瘤小鼠模型中硼替佐米诱导的细胞毒性和抗药性机制的新见解。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-03-07 DOI: 10.1002/hon.3262
Maria Anele Romeo, Chiara Focaccetti, Andrea Arena, Rossella Benedetti, Michele Di Crosta, Camilla Palumbo, Maria Saveria Gilardini Montani, Roberta Santarelli, Roberta Gonnella, Gabriella D’Orazi, Roberto Bei, Mara Cirone
{"title":"New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model","authors":"Maria Anele Romeo,&nbsp;Chiara Focaccetti,&nbsp;Andrea Arena,&nbsp;Rossella Benedetti,&nbsp;Michele Di Crosta,&nbsp;Camilla Palumbo,&nbsp;Maria Saveria Gilardini Montani,&nbsp;Roberta Santarelli,&nbsp;Roberta Gonnella,&nbsp;Gabriella D’Orazi,&nbsp;Roberto Bei,&nbsp;Mara Cirone","doi":"10.1002/hon.3262","DOIUrl":"10.1002/hon.3262","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140049205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of baseline 2-[18F]-FDG-PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis 基线 2-[18 F]-FDG-PET/CT 指标和放射组学特征在预测原发性胃淋巴瘤诊断中的作用。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-03-05 DOI: 10.1002/hon.3266
Domenico Albano, Anna Calabrò, Francesco Dondi, Samuele Bagnasco, Alessandra Tucci, Francesco Bertagna

Diffuse Large B-Cell Lymphomas (DLCBL) and mucosa-associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F]-FDG-PET/CT) and radiomics features (RFs) in predicting the final diagnosis of patients with PGLs. Ninety-one patients with newly diagnosed PGLs who underwent pre-treatment 2-[18F]-FDG-PET/CT were included. PET images were qualitatively and semi-quantitatively analyzed by deriving maximum standardized uptake value body weight (SUVbw), maximum standardized uptake value lean body mass (SUVlbm), maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume (gMTV) and total lesion glycolysis of gastric lesion (gTLG), total MTV (tMTV), TLG, and first-order RFs (histogram-related and shape related). Receiver-operating characteristic (ROC) curve analyses were performed to determine the differential diagnostic values of PET parameters. The final diagnosis was DLBCL in 54 (59%) cases and MALT in 37 cases (41%). PGLs showed FDG avidity in 83 cases (90%), 54/54 of DLBCL and 29/37 of MALT. All PET/CT metabolic features, such as stage of disease and tumor size, were significantly higher in DLBCL than MALT; while the presence of H. Pylori infection was more common in MALT. At univariate analysis, all PET/CT metrics were significantly higher in DLBCL than MALT lymphomas, while among RFs only Shape volume_vx and Shape sphericity showed a significant difference between the two groups. In conclusion we demonstrated that 2-[18F]-FDG-PET/CT parameters can potentially discriminate between DLBCL and MALT lymphomas with high accuracy. Among first-order RFs, only Shape volume_vx and Shape sphericity helped in the differential diagnosis.

弥漫大B细胞淋巴瘤(DLBCL)和粘膜相关淋巴组织淋巴瘤(MALT)是两种最常见的原发性胃淋巴瘤(PGL),但它们的特征却截然不同。DLBCL更具侵袭性,常在晚期确诊,预后较差。这项回顾性研究旨在探讨氟-18-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(2-[18 F]-FDG-PET/CT)和放射组学特征(RFs)在预测PGL患者最终诊断中的作用。91名新确诊的PGL患者在治疗前接受了2-[18 F]-FDG-PET/CT检查。通过得出最大标准化摄取值体重(SUVbw)、最大标准化摄取值瘦体重(SUVlbm)、最大标准化摄取值体表面积(SUVbsa),对 PET 图像进行定性和半定量分析、病变与肝脏的 SUVmax 比值(L-L SUV R)、病变与血池的 SUVmax 比值(L-BP SUV R)、代谢肿瘤体积(gMTV)和胃病变的总病变糖酵解量(gTLG)、总 MTV(tMTV)、TLG 和一阶 RF(直方图相关和形状相关)。为确定 PET 参数的鉴别诊断价值,进行了接收方操作特征(ROC)曲线分析。54例(59%)最终诊断为DLBCL,37例(41%)最终诊断为MALT。83例(90%)PGL显示FDG阳性,其中54/54例为DLBCL,29/37例为MALT。所有 PET/CT 代谢特征,如疾病分期和肿瘤大小,在 DLBCL 中均明显高于 MALT;而幽门螺杆菌感染在 MALT 中更为常见。单变量分析显示,DLBCL淋巴瘤的所有PET/CT指标均明显高于MALT淋巴瘤,而在RFs中,只有Shape volume_vx和Shape sphericity显示两组间存在显著差异。总之,我们证明了 2-[18 F]-FDG-PET/CT 参数能准确区分 DLBCL 和 MALT 淋巴瘤。在一阶射频参数中,只有Shape volume_vx和Shape sphericity有助于鉴别诊断。
{"title":"The role of baseline 2-[18F]-FDG-PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis","authors":"Domenico Albano,&nbsp;Anna Calabrò,&nbsp;Francesco Dondi,&nbsp;Samuele Bagnasco,&nbsp;Alessandra Tucci,&nbsp;Francesco Bertagna","doi":"10.1002/hon.3266","DOIUrl":"10.1002/hon.3266","url":null,"abstract":"<p>Diffuse Large B-Cell Lymphomas (DLCBL) and mucosa-associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[<sup>18</sup>F]-FDG-PET/CT) and radiomics features (RFs) in predicting the final diagnosis of patients with PGLs. Ninety-one patients with newly diagnosed PGLs who underwent pre-treatment 2-[<sup>18</sup>F]-FDG-PET/CT were included. PET images were qualitatively and semi-quantitatively analyzed by deriving maximum standardized uptake value body weight (SUVbw), maximum standardized uptake value lean body mass (SUVlbm), maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume (gMTV) and total lesion glycolysis of gastric lesion (gTLG), total MTV (tMTV), TLG, and first-order RFs (histogram-related and shape related). Receiver-operating characteristic (ROC) curve analyses were performed to determine the differential diagnostic values of PET parameters. The final diagnosis was DLBCL in 54 (59%) cases and MALT in 37 cases (41%). PGLs showed FDG avidity in 83 cases (90%), 54/54 of DLBCL and 29/37 of MALT. All PET/CT metabolic features, such as stage of disease and tumor size, were significantly higher in DLBCL than MALT; while the presence of <i>H. Pylori</i> infection was more common in MALT. At univariate analysis, all PET/CT metrics were significantly higher in DLBCL than MALT lymphomas, while among RFs only Shape volume_vx and Shape sphericity showed a significant difference between the two groups. In conclusion we demonstrated that 2-[<sup>18</sup>F]-FDG-PET/CT parameters can potentially discriminate between DLBCL and MALT lymphomas with high accuracy. Among first-order RFs, only Shape volume_vx and Shape sphericity helped in the differential diagnosis.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy 2020 年各次大流行中与血液恶性肿瘤相关的死亡率:意大利全国范围内多种死因分析。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-02-29 DOI: 10.1002/hon.3263
Enrico Grande, Francesco Grippo, Claudio Barbiellini Amidei, Ugo Fedeli, Alberto Tosetto
{"title":"Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy","authors":"Enrico Grande,&nbsp;Francesco Grippo,&nbsp;Claudio Barbiellini Amidei,&nbsp;Ugo Fedeli,&nbsp;Alberto Tosetto","doi":"10.1002/hon.3263","DOIUrl":"10.1002/hon.3263","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibody targeting of surface P-selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition 以表面 P-选择素糖蛋白配体 1 为靶点的抗体可导致淋巴瘤凋亡并抑制肿瘤发生。
IF 3.3 4区 医学 Q2 Medicine Pub Date : 2024-02-28 DOI: 10.1002/hon.3257
João L. Pereira, Francisca Ferreira, Nuno R. dos Santos

Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P-selectin glycoprotein ligand 1 (PSGL-1) is expressed at the surface of hematological malignant cells and has been shown to have a pro-oncogenic role in multiple myeloma and lymphoma. Here, we investigated the expression and therapeutic potential of PSGL-1 in T and B cell lymphomas. By flow cytometry analysis, we found that PSGL-1 was expressed in both T and B cell-derived lymphoma cell lines but generally at higher levels in T cell lymphoma cell lines. For most T and B cell-derived lymphoma cell lines, in vitro targeting with the PL1 mAb, which recognizes the PSGL-1 N-terminal extracellular region and blocks functional interactions with selectins, resulted in reduced cell viability. The PL1 mAb pro-apoptotic activity was shown to be dose-dependent, to be linked to increased ERK kinase phosphorylation, and to be dependent on the MAP kinase signaling pathway. Importantly, anti-PSGL-1 treatment of mice xenografted with the HUT-78 cutaneous T-cell lymphoma cell line resulted in decreased tumor growth, had no effect on in vivo proliferation, but increased the levels of apoptosis in tumors. Anti-PSGL-1 treatment of mice xenografted with a Burkitt lymphoma cell line that was resistant to anti-PSGL-1 treatment in vitro, had no impact on tumorigenesis. These findings show that PSGL-1 antibody targeting triggers lymphoma cell apoptosis and substantiates PSGL-1 as a potential target for lymphoma therapy.

淋巴瘤是一类起源于 T 细胞、B 细胞或自然杀伤细胞的异质性疾病。淋巴瘤的治疗以化疗、放疗、单克隆抗体(mAb)或其他免疫疗法为主。P 选择素糖蛋白配体 1(PSGL-1)在血液恶性细胞表面表达,已被证明在多发性骨髓瘤和淋巴瘤中具有促癌作用。在这里,我们研究了 PSGL-1 在 T 细胞和 B 细胞淋巴瘤中的表达和治疗潜力。通过流式细胞术分析,我们发现 PSGL-1 在 T 细胞和 B 细胞衍生的淋巴瘤细胞系中均有表达,但一般在 T 细胞淋巴瘤细胞系中表达水平较高。PL1 mAb 能识别 PSGL-1 N 端细胞外区域并阻断其与选择素的功能性相互作用,对于大多数 T 细胞和 B 细胞衍生的淋巴瘤细胞系来说,使用 PL1 mAb 进行体外靶向会导致细胞存活率降低。研究表明,PL1 mAb 促凋亡活性具有剂量依赖性,与 ERK 激酶磷酸化增加有关,并依赖于 MAP 激酶信号通路。重要的是,抗PSGL-1治疗异种移植了HUT-78皮肤T细胞淋巴瘤细胞系的小鼠可减少肿瘤生长,对体内增殖没有影响,但会增加肿瘤的凋亡水平。用对体外抗 PSGL-1 治疗具有抗药性的伯基特淋巴瘤细胞系对异种移植小鼠进行抗 PSGL-1 治疗,对肿瘤发生没有影响。这些研究结果表明,PSGL-1 抗体靶向可引发淋巴瘤细胞凋亡,并证实 PSGL-1 是治疗淋巴瘤的潜在靶点。
{"title":"Antibody targeting of surface P-selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition","authors":"João L. Pereira,&nbsp;Francisca Ferreira,&nbsp;Nuno R. dos Santos","doi":"10.1002/hon.3257","DOIUrl":"10.1002/hon.3257","url":null,"abstract":"<p>Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P-selectin glycoprotein ligand 1 (PSGL-1) is expressed at the surface of hematological malignant cells and has been shown to have a pro-oncogenic role in multiple myeloma and lymphoma. Here, we investigated the expression and therapeutic potential of PSGL-1 in T and B cell lymphomas. By flow cytometry analysis, we found that PSGL-1 was expressed in both T and B cell-derived lymphoma cell lines but generally at higher levels in T cell lymphoma cell lines. For most T and B cell-derived lymphoma cell lines, in vitro targeting with the PL1 mAb, which recognizes the PSGL-1 N-terminal extracellular region and blocks functional interactions with selectins, resulted in reduced cell viability. The PL1 mAb pro-apoptotic activity was shown to be dose-dependent, to be linked to increased ERK kinase phosphorylation, and to be dependent on the MAP kinase signaling pathway. Importantly, anti-PSGL-1 treatment of mice xenografted with the HUT-78 cutaneous T-cell lymphoma cell line resulted in decreased tumor growth, had no effect on in vivo proliferation, but increased the levels of apoptosis in tumors. Anti-PSGL-1 treatment of mice xenografted with a Burkitt lymphoma cell line that was resistant to anti-PSGL-1 treatment in vitro, had no impact on tumorigenesis. These findings show that PSGL-1 antibody targeting triggers lymphoma cell apoptosis and substantiates PSGL-1 as a potential target for lymphoma therapy.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hematological Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1